Robson R A, Wing L M, Miners J O, Lillywhite K J, Birkett D J
Br J Clin Pharmacol. 1985 Aug;20(2):170-3. doi: 10.1111/j.1365-2125.1985.tb05053.x.
The effect of pretreatment with ranitidine (150 mg twice daily for 5 days) on the disposition of lignocaine was examined in 10 healthy volunteers (five male, five female). Each subject received separate oral (250 mg) and intravenous (1.5 mg/kg) doses of lignocaine hydrochloride before and after ranitidine. Lignocaine systemic clearance was reduced by 9% (1.11 to 0.99 1 h-1 kg-1; P less than 0.01) following ranitidine pretreatment. The volume of distribution at steady-state was reduced by 15% (3.34 to 2.85 1 kg-1; P less than 0.005). Lignocaine oral clearance, elimination half-life and oral bioavailability were unchanged after ranitidine pretreatment. There was no sex difference in the effects of ranitidine pretreatment on lignocaine disposition. These results are consistent with small reductions in blood flow to the splanchnic and other vascular beds due to ranitidine.
在10名健康志愿者（5名男性，5名女性）中研究了雷尼替丁预处理（每日两次，每次150毫克，共5天）对利多卡因处置的影响。在服用雷尼替丁前后，每位受试者分别接受了口服（250毫克）和静脉注射（1.5毫克/千克）剂量的盐酸利多卡因。雷尼替丁预处理后，利多卡因的全身清除率降低了9%（从1.11降至0.99升/小时/千克；P<0.01）。稳态分布容积降低了15%（从3.34降至2.85升/千克；P<0.005）。雷尼替丁预处理后，利多卡因的口服清除率、消除半衰期和口服生物利用度未发生变化。雷尼替丁预处理对利多卡因处置的影响不存在性别差异。这些结果与雷尼替丁导致内脏和其他血管床血流量略有减少一致。
